BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28784966)

  • 1. A Human Glioblastoma Organotypic Slice Culture Model for Study of Tumor Cell Migration and Patient-specific Effects of Anti-Invasive Drugs.
    Parker JJ; Lizarraga M; Waziri A; Foshay KM
    J Vis Exp; 2017 Jul; (125):. PubMed ID: 28784966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma.
    Parker JJ; Dionne KR; Massarwa R; Klaassen M; Foreman NK; Niswander L; Canoll P; Kleinschmidt-Demasters BK; Waziri A
    Neuro Oncol; 2013 Aug; 15(8):1048-57. PubMed ID: 23749785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perivascular invasion of primary human glioblastoma cells in organotypic human brain slices: human cells migrating in human brain.
    Ravin R; Suarez-Meade P; Busse B; Blank PS; Vivas-Buitrago T; Norton ES; Graepel S; Chaichana KL; Bezrukov L; Guerrero-Cazares H; Zimmerberg J; Quiñones-Hinojosa A
    J Neurooncol; 2023 Aug; 164(1):43-54. PubMed ID: 37490233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo.
    Jensen SS; Petterson SA; Halle B; Aaberg-Jessen C; Kristensen BW
    BMC Cancer; 2017 Mar; 17(1):178. PubMed ID: 28270132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral heterogeneity of endogenous tumor cell invasive behavior in human glioblastoma.
    Parker JJ; Canoll P; Niswander L; Kleinschmidt-DeMasters BK; Foshay K; Waziri A
    Sci Rep; 2018 Dec; 8(1):18002. PubMed ID: 30573757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An advanced glioma cell invasion assay based on organotypic brain slice cultures.
    Eisemann T; Costa B; Strelau J; Mittelbronn M; Angel P; Peterziel H
    BMC Cancer; 2018 Jan; 18(1):103. PubMed ID: 29378533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of mesenchymal stem cells' secretome on glioblastoma pathophysiology.
    Vieira de Castro J; Gomes ED; Granja S; Anjo SI; Baltazar F; Manadas B; Salgado AJ; Costa BM
    J Transl Med; 2017 Oct; 15(1):200. PubMed ID: 28969635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-lapse phenotyping of invasive glioma cells ex vivo reveals subtype-specific movement patterns guided by tumor core signaling.
    Fayzullin A; Tuvnes FA; Skjellegrind HK; Behnan J; Mughal AA; Langmoen IA; Vik-Mo EO
    Exp Cell Res; 2016 Dec; 349(2):199-213. PubMed ID: 27515001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor compound testing in glioblastoma organotypic brain cultures.
    Biggs T; Foreman J; Sundstrom L; Regenass U; Lehembre F
    J Biomol Screen; 2011 Sep; 16(8):805-17. PubMed ID: 21807962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule agonists of mammalian Diaphanous-related (mDia) formins reveal an effective glioblastoma anti-invasion strategy.
    Arden JD; Lavik KI; Rubinic KA; Chiaia N; Khuder SA; Howard MJ; Nestor-Kalinoski AL; Alberts AS; Eisenmann KM
    Mol Biol Cell; 2015 Nov; 26(21):3704-18. PubMed ID: 26354425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naringenin inhibited migration and invasion of glioblastoma cells through multiple mechanisms.
    Chen YY; Chang YM; Wang KY; Chen PN; Hseu YC; Chen KM; Yeh KT; Chen CJ; Hsu LS
    Environ Toxicol; 2019 Mar; 34(3):233-239. PubMed ID: 30431227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PEITC inhibits human brain glioblastoma GBM 8401 cell migration and invasion through the inhibition of uPA, Rho A, and Ras with inhibition of MMP-2, -7 and -9 gene expression.
    Chou YC; Chang MY; Wang MJ; Yu FS; Liu HC; Harnod T; Hung CH; Lee HT; Chung JG
    Oncol Rep; 2015 Nov; 34(5):2489-96. PubMed ID: 26352173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of an advanced
    Decotret LR; Shi R; Thomas KN; Hsu M; Pallen CJ; Bennewith KL
    Front Oncol; 2023; 13():976945. PubMed ID: 36793608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
    Daher A; de Groot J
    Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain-Mimetic 3D Culture Platforms Allow Investigation of Cooperative Effects of Extracellular Matrix Features on Therapeutic Resistance in Glioblastoma.
    Xiao W; Zhang R; Sohrabi A; Ehsanipour A; Sun S; Liang J; Walthers CM; Ta L; Nathanson DA; Seidlits SK
    Cancer Res; 2018 Mar; 78(5):1358-1370. PubMed ID: 29282221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD90 Expression Controls Migration and Predicts Dasatinib Response in Glioblastoma.
    Avril T; Etcheverry A; Pineau R; Obacz J; Jegou G; Jouan F; Le Reste PJ; Hatami M; Colen RR; Carlson BL; Decker PA; Sarkaria JN; Vauléon E; Chiforeanu DC; Clavreul A; Mosser J; Chevet E; Quillien V
    Clin Cancer Res; 2017 Dec; 23(23):7360-7374. PubMed ID: 28939749
    [No Abstract]   [Full Text] [Related]  

  • 18. Swelling-induced chloride current in glioblastoma proliferation, migration, and invasion.
    Wong R; Chen W; Zhong X; Rutka JT; Feng ZP; Sun HS
    J Cell Physiol; 2018 Jan; 233(1):363-370. PubMed ID: 28262948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of galectin-1 in migration and invasion of human glioblastoma multiforme cell lines.
    Jung TY; Jung S; Ryu HH; Jeong YI; Jin YH; Jin SG; Kim IY; Kang SS; Kim HS
    J Neurosurg; 2008 Aug; 109(2):273-84. PubMed ID: 18671640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.
    Tivnan A; Heilinger T; Ramsey JM; O'Connor G; Pokorny JL; Sarkaria JN; Stringer BW; Day BW; Boyd AW; Kim EL; Lode HN; Cryan SA; Prehn JH
    Oncotarget; 2017 Mar; 8(10):16605-16620. PubMed ID: 28178667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.